Rna Diagnostics has initiated an international prospective clinical trial to validate the RNA Disruption Assay™ (RDA™) a tool for management of primary breast cancer treatment. BREVITY (Breast Cancer Response EValuation for Individualized TherapY) will include 600+ patients with primary breast cancer treatment, scheduled to receive neoadjuvant chemotherapy and targeted drugs, in approximately 40 centers across North America and Europe.
If you would like more information about the BREVITY trial, please contact Dr. Sanaa Noubir at snoubir@rnadiagnostics.com
In a recent study, a high RDA score also proved useful in predicting long-term disease-free survival after neoadjuvant chemotherapy in breast cancer patients.
To access published studies utilizing RDA please click here.